The Dana-Farber Cancer Institute (DFCI) ASHP Accredited PGY2 Oncology Pharmacy Residency is a 12-month postgraduate educational and training experience designed to develop advanced knowledge, skills, and leadership in the delivery of pharmaceutical services to patients with cancer. Residents who successfully complete a PGY2 oncology pharmacy residency at Dana-Farber will be prepared to become proficient and board certified clinical oncology pharmacy practitioners, educators, and leaders.
Residents will gain experience in a variety of areas of clinical oncology practice including: inpatient and outpatient adult solid tumor and hematologic malignancies, stem cell transplant/cellular therapies, palliative care, pediatric oncology, ambulatory infusion pharmacy, and investigational drug services. In addition to providing clinical direct patient care, residents are involved in various educational, safety, administrative, and research projects. These experiences include weekly topic discussions, grand rounds, oral antineoplastic education, medication safety, participation in Pharmacy and Therapeutics Committee, administration, research and academia. Please review our website for additional information. We look forward to meeting.
Residency Program Director: Eno Inyang, PharmD, BCPS, BCOP email@example.com
Applicants must expect to complete an ASHP accredited PGY-1 pharmacy residency and be licensed in the state of Massachusetts by summer of 2020. Application requirements: Complete PhORCAS application by Friday, January 5, 2024.
PPS interviews will be conducted on Sunday, December 3rd through Wednesday, December 6th. For consideration for an interview, please send a message through the PPS messenger. Priority will be given to candidates who submit interview requests by Friday, Nov 17th.
Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to our target community across the United States and throughout the world.
The mission of the Dana-Farber Cancer Institute Pharmacy Department is to provide expert pharmaceutical care to our patients as an integral member of the health care team. The Pharmacy Department also provides clinical and technical training to pharmacy students and pharmacy residents.